GeneQuantum Healthcare

What GeneQuantum Healthcare does

GeneQuantum Healthcare (Suzhou) Co., Ltd. is a privately held Chinese biopharmaceutical company founded in August 2013 and headquartered in Suzhou, with additional offices in Shanghai, San Francisco, and Melbourne. The company develops antibody-drug conjugates (ADCs) and other bioconjugate therapeutics for oncology, serving global pharmaceutical and biotechnology companies exclusively through licensing deals, co-development partnerships, and technology outlicensing rather than direct commercialization. It employs 51-100 people across R&D, manufacturing, and business development.

The company's technology foundation comprises two enzymatic conjugation platforms: iLDC (Intelligent Ligase-Dependent Conjugation), which uses an immobilized engineered transpeptidase, and iGDC (Intelligent Glycotransferase-Dependent Conjugation), which uses an immobilized engineered glycotransferase, both designed to attach payloads at specific antibody sites for high-homogeneity conjugates. These are complemented by a proprietary stable linker-payload platform using cleavable open-ring linkers with topoisomerase I inhibitor payloads, plus supporting platforms including iConjugator (intelligent continuous manufacturing), iScreener (high-throughput screening), and the January 2025-launched iDiscovery (intelligent automated discovery). The clinical-stage pipeline includes GQ1005 (next-generation HER2 ADC in Phase III for HER2-positive breast cancer, 40.9% ORR and Grade 3+ TRAEs below 20% in 188 patients), GQ1001 (HER2 ADC), GQ1010 (Trop2 ADC licensed to Pyramid Biosciences), GQ1011 (first-in-class FGFR3 ADC with Aimed Bio), GQ1007 (first AIAC drug for immune-cold tumors), and earlier-stage GQ1009 and GR-series candidates.

The company monetizes through upfront payments, development/regulatory/sales milestones, and tiered royalties tied to partner net sales. Major deals include the April 2023 exclusive license to Pyramid Biosciences for GQ1010 ($20 million upfront plus up to $1 billion in milestones), a January 2025 major business cooperation exceeding $1.3 billion, and the August 2025 strategic cooperation with Henlius for GQ1005 commercialization in Greater China and selected overseas markets. The company has raised Series A through Series C financing (last round several hundred million RMB in May 2021, led by China Life Private Equity Investment) and was recognized as a "China Potential Unicorn" in 2023 and an "Unicorn-to-be in Jiangsu Province" in 2021.

Name

GeneQuantum Healthcare

Legal name

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Website

https://genequantum.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

GeneQuantum Healthcare is a privately held Chinese clinical-stage biopharmaceutical company developing antibody-drug conjugates for oncology using proprietary enzymatic site-specific bioconjugation platforms (iLDC and iGDC), serving global pharmaceutical partners through licensing, co-development, and technology outlicensing.

Ownership category

akta.pro rank

Product category

Antibody-Drug Conjugates (ADC) Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Antibody-drug conjugates
• Bioconjugate therapeutics
• ADC drug development
• Oncology biopharmaceuticals
• Site-specific conjugation

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Licensing and Milestone Payments: GeneQuantum licenses its proprietary technology platforms and receives upfront payments, development milestones, regulatory milestones, and sales milestones, plus tiered royalties based on net sales. Example: GQ1010 deal with Pyramid Biosciences included $20 million upfront with up to $1 billion in milestones and royalties.
2. Co-development and Collaboration Revenue: Revenue from strategic collaborations including joint ADC development with partners like Aimed Bio (up to 5 ADC drugs), Biocytogen, WuXi XDC, and others. Partners provide resources and GeneQuantum provides technology platforms.
3. Technology Licensing: Non-exclusive licensing of conjugation technology to other biotech/pharmaceutical companies. InxMed deal included upfront payment plus milestone payments and royalties on ADC product sales.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

GeneQuantum Healthcare develops and commercializes antibody-drug conjugates (ADCs) and bioconjugate therapeutics for oncology using proprietary enzymatic site-specific conjugation platforms (iLDC and iGDC). The company advances clinical-stage ADC candidates (GQ1001, GQ1005, GQ1010, GQ1011, GQ1007) and licenses its conjugation technology platforms, linker-payload systems, and intelligent manufacturing platforms to pharmaceutical and biotech partners worldwide.

Product overview

GeneQuantum Healthcare is a global biopharmaceutical innovator specializing in bioconjugate therapeutics, particularly antibody-drug conjugates (ADCs). The company offers an integrated portfolio consisting of multiple clinical-stage ADC products (GQ1001, GQ1005, GQ1010, GQ1011, GQ1007, GQ1009, and GR-series candidates) built on proprietary technology platforms. The core technology infrastructure includes iLDC (intelligent Ligase-dependent Conjugation) and iGDC (intelligent Glycotransferase-dependent Conjugation) enzymatic site-specific conjugation platforms, a Linker-Payload platform with stable cleavable linkers and potent topoisomerase I inhibitors, and GMP manufacturing capabilities. Supporting platforms include iScreener for high-throughput ADC discovery and iConjugation for intelligent continuous manufacturing. The product pipeline spans HER2-targeting ADCs (GQ1001, GQ1005), Trop2-targeting ADC (GQ1010), FGFR3-targeting ADC (GQ1011), and immune-oncology candidates (GQ1007, GQ1009).

Differentiator

Problem solved

Functional benefit

Products and services

• GQ1005 Next-generation HER2-targeting ADC developed using proprietary iLDC technology with a cleavable open-ring linker and topoisomerase I inhibitor payload; designed for HER2 low/medium expressing breast cancer, gastric cancer, NSCLC and other advanced solid tumors; licensed to Henlius for development and commercialization.
• GQ1001 Innovative HER2-targeting ADC developed using iLDC technology and unique ring-opening linker; in global multi-center clinical trials for HER2-positive advanced solid tumors with claimed superior safety profile compared to Kadcyla.
• GQ1010 Next-generation Trop2-targeting ADC developed using iLDC technology, cleavable open-ring linker, and novel topoisomerase I inhibitor; licensed to Pyramid Biosciences with $20M upfront and up to $1B in milestones; targets NSCLC, TNBC and other solid tumors.
• GQ1011

Quantifiable outcome

• GQ1005 achieved ORR of 40.9% in 154 assessable patients and 32.5% in 40 evaluable NSCLC patients with disease control rate of 83.8% and 92.5% respectively
• +4 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Twelve partnerships are on record, tiered flagship, major, minor and core.

• HenliusflagshipStrategic or Co-development Partner · 1 August 2025Strategic cooperation signed August 2025 for development and commercialization of innovative HER2 ADC drug GQ1005. Henlius obtains rights in Mainland China, Hong Kong, Macau and agreed overseas countries. This major partnership aims to advance GQ1005 commercialization leveraging both companies' oncology expertise.
• Johnson & Johnson Innovation JLABS @ ShanghaimajorStrategic or Co-development Partner · 1 July 2024GeneQuantum joined JLABS @ Shanghai as the 100th resident company effective July 26, 2024. By leveraging JLABS global network and resources, GeneQuantum aims to accelerate development of next-generation ADCs with wider therapeutic windows and higher affordability.
• Tsinghua UniversityminorStrategic or Co-development Partner · 1 May 2024Collaboration agreement signed May 2024 with Tsinghua University for academic partnership.
• Nona BiosciencesminorStrategic or Co-development Partner · 1 November 2023Strategic collaboration entered November 2023 for antibody development.
• InxMedcoreOEM/ Whitelabel/ Licensing Partner · 1 July 2023Technology licensing collaboration signed July 2023. GeneQuantum granted non-exclusive licensing of its site-specific glycan conjugation technology (iGDC), stable linker technology, and intelligent continuous conjugation platform to support InxMed's development of next-generation ADC drugs.
• Thousand Oaks BiologicsminorStrategic or Co-development Partner · 1 May 2023Strategic collaboration entered May 2023 for bioconjugate development.
• Intellective BiologicsminorStrategic or Co-development Partner · 1 May 2023Strategic collaboration entered May 2023 for bioconjugate development.
• Pyramid BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 1 April 2023Exclusive licensing agreement for global development and commercialization rights of GQ1010 (excluding Greater China) in April 2023. Deal included $20 million upfront payment with potential for up to $1 billion in milestone payments and tiered royalties based on net sales.
• AsymchemminorStrategic or Co-development Partner · 1 April 2023Strategic collaboration entered April 2023 for ADC drug development support.
• WuXi XDCcoreTechnology or Integration · 1 December 2022Strategic collaboration announced December 2022 for conjugation technology licensing and ADC drug development. WuXi XDC will promote GeneQuantum's proprietary iLDC and iGDC platforms globally to empower innovative bioconjugate development and commercial production using WuXi's integrated CMC capability.
• Aimed BiocoreStrategic or Co-development Partner · 1 April 2022Collaboration starting April 2022 with Korean biotech company Aimed Bio (spun off from Samsung Medical Center) for joint development of first-in-class FGFR3-targeting ADC (GQ1011/AMB302). Expanded in July 2023 to develop up to 5 additional ADC drugs. Results presented at World ADC 2022 and AACR 2023.
• BiocytogencoreStrategic or Co-development Partner · 1 October 2018Strategic cooperation agreement signed October 2018 to integrate GeneQuantum's bio-conjugation platform with Biocytogen's tumor immunotherapy antibody drug development and evaluation platform for joint development of novel bioconjugates for tumor immunotherapy and precision medicine.

Scale indicators7 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• WuXi XDC: WuXi XDC is a leading global CRDMO specializing in ADC discovery, development, and manufacturing. It is both a partner (licensing GeneQuantum's conjugation platforms) and a competitor offering its own end-to-end ADC platform with comparable site-specific conjugation capabilities, targeting the same pharma customer base.
• RemeGen: RemeGen is a Chinese biopharmaceutical innovator with a clinical-stage ADC pipeline including HER2-targeted disitamab vedotin. Competes directly with GeneQuantum in HER2 ADCs and shares the same licensing-out strategy with global pharma partners for its ADC assets.
• Lepu Biopharma: Lepu Biopharma's subsidiary has a notable ADC pipeline including HER2 and Trop2 ADCs and actively pursues licensing deals with multinational pharma. Directly comparable to GeneQuantum as a Chinese ADC innovator pursuing global out-licensing of platform and assets.
• Mabwell Therapeutics: Mabwell is a Chinese biotech with multiple clinical-stage ADCs (HER2, Trop2, Nectin-4 targets) built on proprietary site-specific conjugation. Operates with similar business model — domestic clinical development combined with global licensing — making it a direct ADC competitor.
• Akeso (Akeso Biopharma): Akeso is a Chinese biopharma with a fast-growing oncology biologics pipeline including bispecifics and ADCs. It has executed major global out-licensing deals (e.g., ivonescimab with Summit) and pursues ADC platform partnerships that overlap with GeneQuantum's commercial strategy.
• Mersana Therapeutics: Mersana is a US clinical-stage ADC innovator with proprietary conjugation platforms (Dolasynthen, Immunosynthen) targeting oncology indications. Comparable as a platform-driven ADC company pursuing both proprietary development and platform partnerships with larger pharma.

Broad incumbents

• Innovent Biologics: Innovent is a major Chinese biopharma with oncology biologics, bispecifics, and an emerging ADC pipeline. The CTO of GeneQuantum (Dr. Amy Hong Que) was formerly SVP at Innovent, indicating overlapping talent and a comparable oncology biologics/ADC strategic direction.
• Hansoh Pharmaceutical: Hansoh is a top-tier Chinese pharma with an emerging ADC pipeline and a track record of global out-licensing deals. Operates at a larger scale than GeneQuantum but competes for the same global pharma licensing partners.
• Daiichi Sankyo: Daiichi Sankyo is the global leader in next-generation ADCs (Enhertu, datopotamab deruxtecan) and the benchmark against which GQ1005's HER2 ADC is measured. Comparable as an ADC innovator and commercializer, though at vastly larger scale and with proprietary platform.

Emerging players

• Pyxis Oncology: Pyxis Oncology is a clinical-stage ADC developer with multiple proprietary ADC programs and a focus on novel linker-payload technology. Comparable as an emerging platform ADC innovator targeting oncology partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/genequantum

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneQuantum Healthcare